SCHEMBL1104968

SCHEMBL1104968

CCBOc1ccc(S(=O)(=O)Oc2c(F)c(F)c(F)c(F)c2F)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
TUBB4A P04350 2/20 0.37
TUBB P07437 2/20 0.37
TUBA3C P0DPH7 2/20 0.37
TUBA1B P68363 2/20 0.37
TUBA4A P68366 2/20 0.37
TUBB4B P68371 2/20 0.37
TUBB3 Q13509 2/20 0.37
TUBB2A Q13885 2/20 0.37
TUBB8 Q3ZCM7 2/20 0.37
TUBA3E Q6PEY2 2/20 0.37
TUBA1A Q71U36 2/20 0.37
TUBA1C Q9BQE3 2/20 0.37
TUBB6 Q9BUF5 2/20 0.37
TUBB2B Q9BVA1 2/20 0.37
TUBB1 Q9H4B7 2/20 0.37
GAA P10253 1/20 0.37
MAPK1 P28482 1/20 0.37
CA2 P00918 4/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8769185 0.80 GAA (0.56) TDP1L3MBTL1GAAMAPK1CA2
SCHEMBL952515 0.74 KEAP1 (0.45) GAAMAPK1CA2CA1CA9
SCHEMBL1104955 0.73 SMN1; SMN2 (0.59) L3MBTL1GAAMAPK1CA2CA1
SCHEMBL1104964 0.73 CA2 (0.59) CA2CA1CA9CA12CA7
SCHEMBL1104957 0.73 ALDH1A1 (0.39) TDP1GAACA2CA1CA9
SCHEMBL26317210 0.72 MEN1 (0.40) TDP1GAACA2CA1CA9
SCHEMBL18702916 0.71 CA2 (0.50) CA2CA1CA9CA12CA7
SCHEMBL8623279 0.71 TDP1 (0.50) TDP1MAPK1CA2CA1CA9
SCHEMBL4538720 0.71 PLCG1 (0.45) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL1104972 0.70 LMNA (0.59) L3MBTL1SMN1; SMN2LMNAHTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8907101-B2 Sulfonamide derivatives PFIZER LIMITED (GB) 2014-12-09 US disclosed
US-8541588-B2 Sulfonamide derivatives PFIZER LIMITED (GB) 2013-09-24 US disclosed
US-20120149679-A1 Sulfonamide Derivatives ICAGEN, INC. 2012-06-14 US disclosed
US-8153814-B2 Sulfonamide derivatives PFIZER LIMITED (GB) 2012-04-10 US disclosed
US-20100197655-A1 SULFONAMIDE DERIVATIVES Pfizer Limited Icagen, Inc. 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197655-A1 SULFONAMIDE DERIVATIVES SULT2A1, SULT1A1, TPST2 TDP1 2446/4885L3MBTL1 4732/4885TUBB4A 271/4885
US-20120149679-A1 Sulfonamide Derivatives SULT2A1, SULT1A1, TPST2 TDP1 2446/4885L3MBTL1 4732/4885TUBB4A 271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.